Back to results
US 4,326,055 AGranted
Stilbene derivatives
AssigneeHoffmann-La Roche Inc.
InventorPeter Loeliger
Life of this patent
Estimating the term…
Abstract
This invention is directed to 5,6,7,8-tetrahydro-naphthyl or indanyl stilbene derivatives which are useful as tumor inhibiting agents, in the treatment of neoplasms, dermatological conditions and rheumatic illnesses.
Claims47
Compounds of the formula:
- ##STR7## wherein n is an integer of from 1 and 2 and, when n is 1, R.sup.1 and R.sup.2 are individually hydrogen, lower alkoxy or halogen, or, when n is 2, R.sup.1 is hydrogen, lower alkoxy or halogen and R.sup.2 is hydrogen;
- R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are individually hydrogen or lower alkyl;
- R.sup.7 is hydrogen, methyl or ethyl;
- R.sup.8 and R.sup.9 are hydrogen, lower alkyl or halogen;
- and R.sup.10 is --(CH.dbd.CR.sup.19).sub.m R.sup.11 ;
- m is zero or 1;
- R.sup.11 is ##STR8## or 2-oxazolinyl, or, when m is 1, R.sup.11 is additionally hydrogen;
- R.sup.12 is hydrogen or lower alkyl;
- R.sup.13 is hydrogen, lower alkyl, --N(R.sup.17, R.sup.18) or --OR.sup.14 ;
- R.sup.14 is hydrogen, lower alkyl or alkanoyl;
- R.sup.15 is hydrogen, lower alkyl, --OR.sup.16 or --(CH.sub.2).sub.p N(R.sup.17, R.sup.18);
- R.sup.16 is hydrogen, lower alkyl, hydroxy-(lower alkyl), aryl, substituted aryl, aralkyl or aralkyl substituted in the aryl portion;
- R.sup.17 and R.sup.18 are individually hydrogen or lower alkyl or R.sup.17 and R.sup.18 taken together with the nitrogen atom to which they are attached form a heterocyclic group;
- R.sup.19 is hydrogen or lower alkyl and p is zero, 1, 2 or 3;
- as well as ketals thereof where R.sup.11 is --C(O)R.sup.15 and R.sup.15 is hydrogen or lower alkyl, as well as salts thereof.
12 more elements
Compounds of the formula:
- ##STR11## wherein n is an integer of from 1 and 2 and, when n is 1, R.sup.1 and R.sup.2 are individually hydrogen, lower alkoxy or halogen, or, when n is 2, R.sup.1 is hydrogen, lower alkoxy or halogen and R.sup.2 is hydrogen;
- R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are individually hydrogen or lower alkyl;
- R.sup.7 is hydrogen, methyl or ethyl;
- R.sup.8 and R.sup.9 are hydrogen, lower alkyl or halogen;
- m is zero or 1;
- R.sup.16 is hydrogen, lower alkyl, hydroxy-(lower alkyl), aryl, substituted aryl, aralkyl or aralkyl substituted in the aryl portion;
- R.sup.19 is hydrogen or lower alkyl;
- as well as salts thereof.
5 more elements
A pharmaceutical preparation comprising a compound of the formula:
- ##STR12## wherein n is an integer of from 1 and 2 and, when n is 1, R.sup.1 and R.sup.2 are individually hydrogen, lower alkoxy or halogen, or, when n is 2, R.sup.1 is hydrogen, lower alkoxy or halogen and R.sup.2 is hydrogen;
- R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are individually hydrogen or lower alkyl;
- R.sup.7 is hydrogen, methyl or ethyl;
- R.sup.8 and R.sup.9 are hydrogen, lower alkyl or halogen;
- and R.sup.10 is --(CH.dbd.CR.sup.19).sub.m R.sup.11 ;
- m is zero or 1;
- R.sup.11 is ##STR13## or 2-oxazolinyl, or, when m is 1, R.sup.11 is additionally hydrogen;
- R.sup.12 is hydrogen or lower alkyl;
- R.sup.13 is hydrogen, lower alkyl, --N(R.sup.17, R.sup.18) or --OR.sup.14 ;
- R.sup.14 is hydrogen, lower alkyl or alkanoyl;
- R.sup.15 is hydrogen, lower alkyl, --OR.sup.16 or --(CH.sub.2).sub.p N(R.sup.17, R.sup.18);
- R.sup.16 is hydrogen, lower alkyl, hydroxy-(lower alkyl), aryl, substituted aryl, aralkyl or aralkyl substituted in the aryl portion;
- R.sup.17 and R.sup.18 are individually hydrogen or lower alkyl or R.sup.17 and R.sup.18 taken together with the nitrogen atom to which they are attached form a heterocyclic group;
- R.sup.19 is hydrogen or lower alkyl and p is zero, 1, 2 or 3;
- as well as ketals thereof where R.sup.11 is --C(O)R.sup.15 and R.sup.15 is hydrogen or lower alkyl, or a salt thereof
- and an inert pharmaceutically effective carrier.
13 more elements
The process of treating neoplasms, dermatological conditions or rheumatic illness comprising administering to a patient a composition containing an effective amount of a compound of the formula:
- ##STR14## wherein n is an integer of from 1 and 2 and, when n is 1, R.sup.1 and R.sup.2 are individually hydrogen, lower alkoxy or halogen, or, when n is 2, R.sup.1 is hydrogen, lower alkoxy or halogen and R.sup.2 is hydrogen;
- R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are individually hydrogen or lower alkyl;
- R.sup.7 is hydrogen, methyl or ethyl;
- R.sup.8 and R.sup.9 are hydrogen, lower alkyl or halogen;
- and R.sup.10 is --(CH.dbd.CR.sup.19).sub.m R.sup.11 ;
- m is zero or 1;
- R.sup.11 is ##STR15## or 2-oxazolinyl, or, when m is 1, R.sup.11 is additionally hydrogen;
- R.sup.12 is hydrogen or lower alkyl;
- R.sup.13 is hydrogen, lower alkyl, --N(R.sup.17, R.sup.18) or --OR.sup.14 ;
- R.sup.14 is hydrogen, lower alkyl or alkanoyl;
- R.sup.15 is hydrogen, lower alkyl, --OR.sup.16 or --(CH.sub.2).sub.p N(R.sup.17, R.sup.18);
- R.sup.16 is hydrogen, lower alkyl, hydroxy-(lower alkyl), aryl, substituted aryl, aralkyl or aralkyl substituted in the aryl portion;
- R.sup.17 and R.sup.18 are individually hydrogen or lower alkyl or R.sup.17 and R.sup.18 taken together with the nitrogen atom to which they are attached form a heterocyclic group;
- R.sup.19 is hydrogen or lower alkyl and p is zero, 1, 2 or 3;
- as well as ketals thereof where R.sup.11 is --C(O)R.sup.15 and R.sup.15 is hydrogen or lower alkyl, or a salt thereof;
- and inert pharmaceutically acceptable carrier.
13 more elements
Dependencies are inferred from the claim text.